From December 17 to 19, 2023, the 2023 Academic Forum on Precision Radiotherapy and Oncology MDT was successfully held in Beijing. The forum was sponsored by Precision Radiotherapy Technology Branch of Chinese Society of Biomedical Engineering, Multidisciplinary Diagnosis and Treatment Branch of Chinese Aging Well Association, and jointly hosted by Sino-Israeli Health Alliance International (SIHA) Medical Technology Co., Ltd..

More than 60 radiotherapy experts from all over the country and overseas, together with industry colleagues participated in the forum (online + offline), to exchange their research results and introduce the latest radiotherapy products.

Many experts were invited to attend this forum, including Professor Zhu Guangying and Professor Mao Kai from Radiotherapy Department of China-Japan Friendship Hospital, Professor Kang Jingbo, director of Radiotherapy Department of the Sixth Medical Center of PLA General Hospital, Professor Hu Yong from Radiotherapy Department of Fudan University Zhongshan Hospital, and Professor Zhang Yanshan, vice president of Gansu Wuwei Heavy Ion Hospital. They gave fascinating presentations themed on multidisciplinary diagnosis and treatment of tumors, motion management of abdominal tumor radiotherapy, application of high-frequency oscillatory ventilation (HFOV) machine in general anesthesia in heavy ion therapy and so on.

Michael Marash, founder and CEO of P-Cure Group and chief scientist of SIHA, was invited to participate in the forum. Dr. Marash made a presentation on “Motion Management Approach in Treating Patients Seated with the Most Compact Synchrotron-Based Delivery Proton Therapy System”, focusing on P-Cure’s 4D CT and respiratory gating technology. Combined with P-Cure’s unique seated-position treatment, it targets lesions precisely with radiation beams, reducing the impact of respiratory movement, and better protecting the normal tissue surrounding the tumor while destroying the tumor cells. Compared with traditional radiotherapy technologies, 4D CT and respiratory gating technology have the advantages of fewer side effects and more accurate tumor attack, which can significantly prolong the survival period and improve the quality of life of tumor patients.

Dr. Marash also shared the complete process of treating patients with P-Cure proton system via video. P-Cure is working with Hadassah Medical Center to conduct clinical trials of the P-Cure ultra-compact proton therapy system in Israel, and has already completed 50 cases of oncology patients covering a wide range of indications such as head and neck, thoracic, abdominal tumors, etc. The P-Cure ultra-compact seated-position proton therapy system combined with respiratory gating technology  provides tumor patients with more accurate, more comfortable and more effective radiotherapy treatment.